AR032575A1 - Uso de una preparacion antigenica de gripe para la fabricacion de una vacuna intradermica de la gripe y estuche farmaceutico que comprende dicha vacuna - Google Patents

Uso de una preparacion antigenica de gripe para la fabricacion de una vacuna intradermica de la gripe y estuche farmaceutico que comprende dicha vacuna

Info

Publication number
AR032575A1
AR032575A1 ARP020100594A ARP020100594A AR032575A1 AR 032575 A1 AR032575 A1 AR 032575A1 AR P020100594 A ARP020100594 A AR P020100594A AR P020100594 A ARP020100594 A AR P020100594A AR 032575 A1 AR032575 A1 AR 032575A1
Authority
AR
Argentina
Prior art keywords
vaccine
flu
manufacture
virus
intradermic
Prior art date
Application number
ARP020100594A
Other languages
English (en)
Spanish (es)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0104542A external-priority patent/GB0104542D0/en
Priority claimed from GB0108366A external-priority patent/GB0108366D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of AR032575A1 publication Critical patent/AR032575A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP020100594A 2001-02-23 2002-02-21 Uso de una preparacion antigenica de gripe para la fabricacion de una vacuna intradermica de la gripe y estuche farmaceutico que comprende dicha vacuna AR032575A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0104542A GB0104542D0 (en) 2001-02-23 2001-02-23 Novel vaccine
GB0108366A GB0108366D0 (en) 2001-04-03 2001-04-03 Novel compounds

Publications (1)

Publication Number Publication Date
AR032575A1 true AR032575A1 (es) 2003-11-12

Family

ID=26245752

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100594A AR032575A1 (es) 2001-02-23 2002-02-21 Uso de una preparacion antigenica de gripe para la fabricacion de una vacuna intradermica de la gripe y estuche farmaceutico que comprende dicha vacuna

Country Status (6)

Country Link
US (2) US20040096463A1 (enExample)
EP (1) EP1361889A1 (enExample)
JP (1) JP2004536785A (enExample)
AR (1) AR032575A1 (enExample)
CA (1) CA2438960A1 (enExample)
WO (1) WO2002067983A1 (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60036952T2 (de) * 1999-09-24 2008-08-07 Glaxosmithkline Biologicals S.A. Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
US20040071734A1 (en) * 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
GB2386072A (en) * 2001-04-27 2003-09-10 Becton Dickinson Co Novel vaccine
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
CA2451816A1 (en) * 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
US7588774B2 (en) 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
CA2503774C (en) 2003-06-20 2007-09-25 Microbix Biosystems Inc. Improvements in virus production
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
JP2007530680A (ja) 2004-04-01 2007-11-01 アルザ・コーポレーシヨン インフルエンザワクチンの経皮デリバリーのための装置および方法
WO2005113756A1 (en) * 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
WO2006062637A2 (en) * 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics Inc. Influenza vaccination
US20070292386A9 (en) * 2004-12-02 2007-12-20 Campbell Robert L Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
DE602006019629D1 (de) 2005-11-01 2011-02-24 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
DE202006021242U1 (de) * 2005-11-04 2014-01-29 Novartis Vaccines And Diagnostics S.R.L. Emulsionen mit freiem wässrigen Phasen Tensid als Adjuvans für Spalt-Grippeimpfstoffe
ES2792398T3 (es) 2005-11-04 2020-11-11 Seqirus Uk Ltd Vacunas adyuvantadas con antígenos de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
ATE539765T1 (de) 2005-11-04 2012-01-15 Novartis Vaccines & Diagnostic Grippeimpfstoffe mit kombinationen aus teilchenförmigen adjuvantien und immunverstärkern
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US20110027314A1 (en) 2006-01-27 2011-02-03 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Influenza Vaccines Containing Hemagglutinin and Matrix Proteins
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008032219A2 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
SG182957A1 (en) 2007-06-27 2012-08-30 Novartis Ag Low-additive influenza vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2235532B1 (en) 2007-12-24 2013-04-24 Novartis AG Assays for adsorbed influenza vaccines
US8506966B2 (en) * 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
CN101998990B (zh) 2008-03-18 2013-11-27 诺华股份有限公司 流感病毒疫苗抗原制备方法的改进
RU2011107757A (ru) 2008-08-01 2012-09-10 Гамма Ваксинс Пти Лимитед (Au) Вакцины против гриппа
CA2741961A1 (en) 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
WO2010089339A1 (en) * 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Purification of virus or viral antigens by density gradient ultracentrifugation
AU2010212548A1 (en) 2009-02-10 2011-09-15 Novartis Ag Influenza vaccines with increased amounts of H3 antigen
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
EP2424565A1 (en) 2009-04-27 2012-03-07 Novartis AG Adjuvanted vaccines for protecting against influenza
WO2010133964A1 (en) 2009-05-21 2010-11-25 Novartis Ag Reverse genetics using non-endogenous pol i promoters
US9821052B2 (en) 2009-07-31 2017-11-21 Seqirus UK Limited Reverse genetics systems
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
CN102741399A (zh) 2009-10-20 2012-10-17 诺华有限公司 用于病毒拯救的改良反向遗传方法
EA201291179A1 (ru) 2010-05-06 2013-04-30 Новартис Аг Органические пероксидные соединения для инактивации микроорганизмов
US8945904B2 (en) 2010-05-21 2015-02-03 Novartis Ag Influenza virus reassortment
WO2011151726A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
EP2575872B1 (en) 2010-06-01 2020-08-19 Seqirus UK Limited Concentration of influenza vaccine antigens without lyophilization
WO2011154976A2 (en) 2010-06-08 2011-12-15 Panacea Biotec Limited Improved influenza vaccine
CA2808965C (en) 2010-08-20 2020-01-07 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
EP2667891B1 (en) 2011-01-27 2021-10-06 Gamma Vaccines Pty Limited Combination vaccines
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
US20140248320A1 (en) 2011-10-20 2014-09-04 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
AU2013205478B9 (en) 2012-03-02 2014-11-20 Seqirus UK Limited Influenza virus reassortment
RU2599496C2 (ru) 2012-03-06 2016-10-10 Круселл Холланд Б.В. Улучшенная вакцинация против гриппа
HK1208502A1 (en) 2012-06-04 2016-03-04 Novartis Ag Improved safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
US9708585B2 (en) 2012-12-03 2017-07-18 Seqirus UK Limited Influenza virus reassortment
JP2016506416A (ja) 2013-01-10 2016-03-03 ノバルティス アーゲー インフルエンザウイルス免疫原性組成物およびその使用
AU2014229255B2 (en) 2013-03-13 2018-12-13 Novartis Ag Influenza B virus reassortment
US20140335116A1 (en) 2013-05-10 2014-11-13 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
CA2914604A1 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
KR20160068972A (ko) 2013-11-15 2016-06-15 노파르티스 아게 잔여 세포 배양 불순물의 제거
FR3025107B1 (fr) 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
HK1254344A1 (zh) 2015-06-26 2019-07-19 Seqirus UK Limited 抗原匹配的流感疫苗
JP6830070B2 (ja) 2015-07-07 2021-02-17 セキラス ユーケー リミテッドＳｅｑｉｒｕｓ ＵＫ Ｌｉｍｉｔｅｄ インフルエンザ効力アッセイ
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN111511800B (zh) 2017-10-30 2023-11-28 武田药品工业株式会社 灭活脂包膜病毒的环境相容性去污剂
MX2021010194A (es) 2019-02-25 2022-01-24 Seqirus Uk Ltd Vacunas contra la influenza multivalentes adyuvantadas.
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
CN114929270A (zh) 2019-11-07 2022-08-19 塞其里斯英国有限公司 用于生产具有减小的颗粒大小的病毒疫苗的组合物和方法
IL293031A (en) 2019-11-18 2022-07-01 Seqirus Pty Ltd Method for producing reassortant influenza viruses
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
IT202100014747A1 (it) * 2021-06-07 2022-12-07 Consiglio Nazionale Ricerche Derivati sterolici come nuovi ligandi del recettore dectina-1 nel trattamento terapeutico di patologie correlate a tale recettore

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1274081A (en) * 1917-05-10 1918-07-30 Herman A Metz Hypodermic needle.
US1436707A (en) * 1921-08-10 1922-11-28 American Platinum Works Adjustable and safety regulating device for hypodermic needles
FR1001668A (fr) * 1946-06-17 1952-02-26 Seringue pour anesthésie tronculaire du maxillaire inférieur
US2559474A (en) * 1950-03-09 1951-07-03 Sonco Inc Hypodermic and spinal syringe
FR1072399A (fr) * 1961-01-07 1954-09-13 Injecteur intra-dermique
US3400715A (en) * 1966-01-04 1968-09-10 Halvard J. Pederson Attachment for injection apparatus
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
BE795384A (fr) * 1972-02-14 1973-08-13 Ici Ltd Pansements
JPS6153226A (ja) * 1984-08-24 1986-03-17 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニツトワクチンの精製方法
CA1283827C (en) * 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
US6056716A (en) * 1987-06-08 2000-05-02 D'antonio Consultants International Inc. Hypodermic fluid dispenser
US5569190A (en) * 1987-06-08 1996-10-29 D'antonio; Nicholas F. Hypodermic fluid dispenser
US5080648A (en) * 1987-06-08 1992-01-14 Antonio Nicholas F D Hypodermic fluid dispenser
US5195526A (en) * 1988-03-11 1993-03-23 Michelson Gary K Spinal marker needle
TW279133B (enExample) * 1990-12-13 1996-06-21 Elan Med Tech
SE9102652D0 (sv) * 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) * 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
IL101720A (en) * 1992-04-29 1998-09-24 Mali Tech Ltd Needle for syringe or the like
US5686078A (en) * 1992-09-14 1997-11-11 Connaught Laboratories, Inc. Primary and secondary immunization with different physio-chemical forms of antigen
CN1124013A (zh) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
EP0684838A1 (en) * 1993-02-19 1995-12-06 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
US6485729B1 (en) * 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
US5997501A (en) * 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
SE9502285D0 (sv) * 1995-06-22 1995-06-22 Pharmacia Ab Improvements related to injections
US5776107A (en) * 1996-12-31 1998-07-07 Delab Injection device
IT1298087B1 (it) * 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6494865B1 (en) * 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US6569123B2 (en) * 1999-10-14 2003-05-27 Becton, Dickinson And Company Prefillable intradermal injector
US6776776B2 (en) * 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US20020193740A1 (en) * 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
US6569143B2 (en) * 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
US20040071734A1 (en) * 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB2386072A (en) * 2001-04-27 2003-09-10 Becton Dickinson Co Novel vaccine
CA2451816A1 (en) * 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula

Also Published As

Publication number Publication date
JP2004536785A (ja) 2004-12-09
US20040096463A1 (en) 2004-05-20
US20140302090A1 (en) 2014-10-09
EP1361889A1 (en) 2003-11-19
WO2002067983A1 (en) 2002-09-06
CA2438960A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
AR032575A1 (es) Uso de una preparacion antigenica de gripe para la fabricacion de una vacuna intradermica de la gripe y estuche farmaceutico que comprende dicha vacuna
ATE331530T1 (de) Proteasom-influenzavirus-impfstoffzusammensetzu g
CY1122869T1 (el) Πολυπεπτιδικα εμβολια για ευρεια προστασια εναντι υπερλοιμογονων μηνιγγιτιδοκοκκικων γενεαλογικων σειρων
UY26882A1 (es) Nuevo tratamiento
ES2139553T1 (es) Replicacion de virus de la gripe en un cultivo de celulas de mamiferos y produccion de vacuna.
JP2004536785A5 (enExample)
JP2004532830A5 (enExample)
AR059772A1 (es) Composiciones que incuyen hemaglutinina metodos de elaboracion y metodos de uso de las mismas
AR061894A1 (es) Vacunas para malaria
CO2022009288A2 (es) Métodos de cultivo de células, preparación de hidrolizado a partir de células y aplicaciones de los mismos
ES2421543T3 (es) Método para la preparación de virus y proteínas del PRRS, y kits de pruebas de diagnóstico para su detección
AR004464A1 (es) Un metodo para producir una proteina de capside de papilomavirus
Jungbauer Exosomes enter vaccine development: strategies meeting global challenges of emerging infections
Marín-López et al. Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR (−/−) mice conferring protection against serotypes 1 and 4 of bluetongue virus
AR021414A1 (es) Formulaciones conteniendo particulas semejantes a virus como inmunopotenciadores por via mucosal
Wyde et al. Use of cotton rats for preclinical evaluation of measles vaccines
AR009365A1 (es) Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno
FR2803307A1 (fr) Lignees de lymphocytes t cd4 specifiques de type th1 et procede pour leur induction ex vivo
AR023534A1 (es) Vacuna.
ES2542020T3 (es) Vacunación antigripal
Gao et al. Identification of two novel foot-and-mouth disease virus cytotoxic T lymphocyte epitopes that can bind six SLA-I proteins
ES2067916T3 (es) Matriz con celulas fijadas por adherencia y procedimiento de produccion de virus/antigenos de virus.
Berinstein et al. Enhancement of the immune response elicited with foot-and-mouth disease virus vaccines by an extract of the Mycobacterium sp. wall
AR027291A1 (es) Atenuacion recombinante de prrsv
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano

Legal Events

Date Code Title Description
FA Abandonment or withdrawal